X

Trial Profile

Phase I Study of Intratumoral Administration of HF10, Oncolytic Herpes Simplex Virus Type 1, in Patients with Advanced Unresectable Pancreatic Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Feb 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Canerpaturev (Primary) ; Erlotinib; Gemcitabine
Indications Pancreatic cancer
Focus Adverse reactions

Most Recent Events

11 Apr 2016 Status changed from recruiting to active, no longer recruiting.
30 Apr 2013 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
18 Apr 2013 Planned initiation date changed from May 2013 to 30 Apr 2013 as reported by University Hospital Medical Information Network - Japan.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com